Experienced in Disseminated Intravascular Coagulation

Huiying Y. Qiu

No. 100 Haining Road, 
Shanghai, CN 
Experienced in Disseminated Intravascular Coagulation
No. 100 Haining Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Huiying Qiu practices in Shanghai, China. Qiu is rated as an Experienced expert by MediFind in the treatment of Disseminated Intravascular Coagulation. Their top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 259 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Disseminated Intravascular Coagulation.

Locations

No. 100 Haining Road, Shanghai, 200080, China
Other Locations
188 Shizi Street, Suzhou, 215006, China
160 Pujian Road, Shanghai, 200127, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients with Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia
CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients with Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Biological
Study Drug: CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

259 Total Publications

Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.
Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.
Journal: Cell transplantation
Published: October 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Qiu's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile